Peptonic enters commercial supply agreement with Orion
Stockholm April 24th, 2018 - Peptonic Medical AB (publ) (’Peptonic’ eller ’Company’) today announced that it has entered an agreement for the commercial supply of its hormone-free selfcare product VagiVital® with Orion Corporation (‘Orion’), with headquarters in Espoo, Finland. The supply agreement is non-exclusive and a result of a successful transfer of the manufacturing technology under the technology transfer agreement signed by the two companies in December 2017. Under the new supply agreement, Orion undertakes to manufacture agreed quantities of VagiVital® to predetermined quality specifications and agreed prices, whereas Peptonic undertakes to buy certain minimum quantities of VagiVital® from Orion.
- Orion has met all our expectations during the collaboration concerning the technology transfer and we have great confidence in Orion’s competence within manufacturing and logistics, says Johan Inborr, CEO of Peptonic. We look forward to a long lasting cooperation with Orion.
Peptonic plans to launch VagiVital® during 2018. Before the product can be marketed and sold it needs to be CE marked. The process of obtaining the CE mark is in its final stage.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
E-mail: johan.inborr@peptonicmedical.se
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 24 April 2018.
About Orion
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's adjusted net sales in 2017 amounted to EUR 1,034 million and the company had about 3,200 employees. Orion's A and B shares are listed on Nasdaq Helsinki.
For more information: www.orion.fi/en
About Peptonic Medical
Peptonic Medical is an innovative Swedish development company. Our vision is to offer safe and effective treatments for women suffering from vaginal atrophy during menopause and after.
VagiVital® is a trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy.
The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
In July 2014, Peptonic Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.
For more information: www.peptonicmedical.com
About VagiVital®
VagiVital® is a hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
Peptonic Medical plans to launch VagiVital® as a non-prescription self-care product in 2018.